12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
BenzingaApr 12 08:09 ET
HCW Biologics: A Strong Buy on Promising Clinical Results and Strategic Advancements
TipRanksApr 4 14:45 ET
Express News | HCW Biologics Q4 2023 GAAP EPS $(0.15) Misses $(0.14) Estimate, Sales $1.341M Beat $900.000K Estimate
Moomoo 24/7Apr 1 16:17 ET
HCW Biologics: Continue With Other Fundraising Efforts That We Are Targeting to Complete in the Next Three to Six Mos >HCWB
HCW Biologics: Continue With Other Fundraising Efforts That We Are Targeting to Complete in the Next Three to Six Mos >HCWB
Dow JonesApr 1 16:17 ET
HCW Biologics: As of Dec 31, 2023, There Was Substantial Doubt About Our Ability to Continue as a Going Concern >HCWB
HCW Biologics: As of Dec 31, 2023, There Was Substantial Doubt About Our Ability to Continue as a Going Concern >HCWB
Dow JonesApr 1 16:16 ET
HCW Biologics: Since That Time Successful Financings of $12.5M, Have Received Funds or Have Legally Binding Commitment to So >HCWB
HCW Biologics: Since That Time Successful Financings of $12.5M, Have Received Funds or Have Legally Binding Commitment to So >HCWB
Dow JonesApr 1 16:16 ET
HCW Biologics 4Q Loss/Shr 30c >HCWB
HCW Biologics 4Q Loss/Shr 30c >HCWB
Dow JonesApr 1 16:14 ET
HCW Biologics 4Q Rev $252,646 >HCWB
HCW Biologics 4Q Rev $252,646 >HCWB
Dow JonesApr 1 16:14 ET
Press Release: HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
HCW Biologics Inc. today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
Dow JonesApr 1 16:10 ET
Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
Those following along with HCW Biologics Inc. (NASDAQ:HCWB) will no doubt be intrigued by the recent purchase of shares by Rebecca Byam, Chief Financial Officer of the company, who spent a stonking US
Simply Wall StFeb 28 07:31 ET
HCW Biologics Executives Boost Investment With Share Purchase
TipRanksFeb 22 08:53 ET
Express News | HCW Biologics Said Terminated Its Credit Agreement With Prime Capital Ventures Dated April 21, 2023, As Allowed Under The Agreement Terms, Due To Repeated Funding Delays And Related Concerns
Moomoo 24/7Jan 12 07:33 ET
HCW Biologics Receives Buy Rating: Strong Financial Position and Promising Clinical Data Validate Investment Opportunity
TipRanksNov 16, 2023 14:45 ET
Analysts Are Bullish on Top Healthcare Stocks: HCW Biologics (HCWB), Urogen Pharma (URGN)
TipRanksNov 14, 2023 14:11 ET
HCW Biologics GAAP EPS of -$0.14, Revenue of $174.77M
Seeking AlphaNov 14, 2023 09:30 ET
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102
07:12 AM EST, 11/14/2023 (MT Newswires) -- Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102
MT NewswiresNov 14, 2023 07:12 ET
HCW Biologics 3Q Rev $174,777 >HCWB
HCW Biologics 3Q Rev $174,777 >HCWB
Dow JonesNov 14, 2023 07:07 ET
Promising Phase 1 Results and Potential Synergies With PD-1 Inhibitors Bolster Buy Rating for HCW Biologics
TipRanksNov 10, 2023 13:16 ET
Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR,
GlobeNewswireNov 8, 2023 07:30 ET
Promising Clinical Data and Future Plans Boost HCW Biologics: An Analysis of Soumit Roy's Buy Recommendation
TipRanksNov 6, 2023 17:55 ET
No Data
No Data